Austrailian technology
Posted: Thu Feb 15, 2007 6:04 pm
This is a technology they are developing in Australia. Its called Kappacin. It is still in early stages but sounds interesting.
This company also said they found that "bacteria living in the body can be 500 times more resistant to anti-microbial agents than those same bacteria grown in the laboratory."
I dont know did they apply this to there own study below though.
This may explain why things like bliss work in a lab but has no effect in our mouths.
Kappacin is a novel antimicrobial peptide derived from bovine milk κ-casein. Kappacin has been shown to have in vitro antibacterial activity against both Gram-positive and Gram-negative oral bacteria. Streptococcus mutans and Lactobacillus casei have been strongly implicated in the initiation and progression of human dental caries, whilst Fusobacterium nucleatum has been implicated in halitosis.
Objective:
To evaluate the antibacterial activity of KappaZinc against a polymicrobial oral biofilm.
Method:
To simulate a simplified supragingival plaque Streptococcus sanguis, S. mutans, Actinomyces naeslundii, Veillonella dispar, L. casei and F. nucleatum were cultured as a biofilm using an artificial saliva medium supplemented with a four times daily addition of a starch, sucrose and protein mixture.
After the biofilm stabilized, 5 ml of a mixture of 1% Kappacin with 20 mM ZnCl2 was added four times daily. Viable counts with selective media were used to determine biofilm species composition.
Result:
KappaZinc treatment reduced total bacterial viability by 88% and the viability of both V. dispar and F. nucleatum, S. sanguis, S. mutans, A. naeslundii and L. casei by 98%, 92%, 85%, 55% and 89%, respectively. KappaZinc also suppressed the recovery of S. mutans and L. casei after treatment resulting in a shift in species composition favouring less acidogenic species.
Conclusion:
KappaZinc has efficacy against oral polymicrobial biofilms and may have potential for future oral health applications.
This company also said they found that "bacteria living in the body can be 500 times more resistant to anti-microbial agents than those same bacteria grown in the laboratory."
I dont know did they apply this to there own study below though.
This may explain why things like bliss work in a lab but has no effect in our mouths.
Kappacin is a novel antimicrobial peptide derived from bovine milk κ-casein. Kappacin has been shown to have in vitro antibacterial activity against both Gram-positive and Gram-negative oral bacteria. Streptococcus mutans and Lactobacillus casei have been strongly implicated in the initiation and progression of human dental caries, whilst Fusobacterium nucleatum has been implicated in halitosis.
Objective:
To evaluate the antibacterial activity of KappaZinc against a polymicrobial oral biofilm.
Method:
To simulate a simplified supragingival plaque Streptococcus sanguis, S. mutans, Actinomyces naeslundii, Veillonella dispar, L. casei and F. nucleatum were cultured as a biofilm using an artificial saliva medium supplemented with a four times daily addition of a starch, sucrose and protein mixture.
After the biofilm stabilized, 5 ml of a mixture of 1% Kappacin with 20 mM ZnCl2 was added four times daily. Viable counts with selective media were used to determine biofilm species composition.
Result:
KappaZinc treatment reduced total bacterial viability by 88% and the viability of both V. dispar and F. nucleatum, S. sanguis, S. mutans, A. naeslundii and L. casei by 98%, 92%, 85%, 55% and 89%, respectively. KappaZinc also suppressed the recovery of S. mutans and L. casei after treatment resulting in a shift in species composition favouring less acidogenic species.
Conclusion:
KappaZinc has efficacy against oral polymicrobial biofilms and may have potential for future oral health applications.